Mesa Labs reported a 60% increase in revenue for Q3 2022, driven by organic growth and acquisitions. However, the company experienced a decrease in operating income and reported a net loss, impacted by unusual items related to acquisitions and other adjustments.
Revenues increased by 60% compared to the same quarter last year, reaching $54,696 thousand.
Operating loss was $(2,512) thousand, a significant decrease compared to the prior year's operating income of $22 thousand.
Net loss was $(2,060) thousand, or $(0.39) per diluted share.
Organic revenue growth was 12% for the quarter.
Mesa Labs completed the acquisition of Agena Bioscience and anticipates continued organic revenue and profitability growth, despite ongoing pandemic-related headwinds, with the Mesa Way operating model.
Visualization of income flow from segment revenue to net income